A cross-sectional analysis of 41 clinical studies from 1997-2022 revealed underrepresentation of Hispanic, Black, and Asian participants in pediatric ophthalmology research.

A recent study presented at the European Society of Cardiology Congress 2024 reveals that recreational drug use triples the risk of repeat cardiovascular events within one year of hospitalization.

A new study reveals that metformin, a common diabetes drug, can slow the growth of precancerous cells in the esophagus.

The European Medicines Agency (EMA) has upheld its rejection of Apellis' pegcetacoplan (Syfovre) for treating geographic atrophy (GA).

Researchers found that activating the pentose phosphate pathway in T cells enhances their anti-tumor activity when combined with checkpoint inhibitors.

Alexander Fanaroff, MD, MHS, will present lessons from the BE ACTIVE randomized clinical trial on October 18, 2024.

The European Medicines Agency (EMA) has recommended Leqembi for treating early-stage Alzheimer's, reversing its initial rejection due to brain swelling risks.

Bioretec partners with Tri-State Biologics to expand the distribution of RemeOs bioresorbable implants in the U.S., targeting the New York City, Philadelphia, and New Jersey areas.

A comprehensive meta-analysis of 40 randomized clinical trials involving 11,576 patients evaluated various locoregional therapies (LRTs) for nonmetastatic hepatocellular carcinoma (HCC).

Ziftomenib, a selective menin inhibitor, demonstrates promising clinical activity in relapsed/refractory AML patients, especially those with _NPM1_ mutations or _KMT2A_ rearrangements.

A long-term safety analysis of omaveloxolone, the first FDA-approved treatment for Friedreich ataxia, shows a positive safety profile, offering reassurance for its use.

AstraZeneca's DAPA-MI trial demonstrates the feasibility of registry-based randomized clinical trials (R-RCTs) in drug development.

The European Medicines Agency's CHMP has recommended marketing authorization for Selincro (nalmefene), developed by Lundbeck and Biotie, for reducing alcohol consumption in alcohol-dependent adults.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the preferred term for non-alcoholic fatty liver disease (NAFLD), reflecting a shift towards metabolic dysfunction as the primary driver.

A new blood test combining CA199.STRA and CA19-9 biomarkers significantly improves the detection rate of early-stage pancreatic cancer compared to the standard CA19-9 test alone.

A study in Kenya found that a 40% fractional dose of Pfizer's PCV13 vaccine provided non-inferior immunogenicity compared to a full dose in infants.

A new study reveals that 5-fluorouracil (5-FU) kills gastrointestinal cancer cells primarily by interfering with RNA synthesis, not DNA damage, challenging long-held beliefs.

E-cigarettes, initially seen as a smoking cessation tool, have led to a new wave of nicotine addiction, with many users finding it difficult to quit vaping.

Electroconvulsive therapy (ECT) is being explored for managing behavioral and psychological symptoms of dementia, addressing a critical unmet need.

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Novo Nordisk's concizumab for hemophilia treatment.